Suggestions
Daniel Veres MD PhD
Chief Scientific Officer & Co-Founder @ Turbine
Daniel Veres MD PhD is a medical doctor, cancer researcher, and entrepreneur who serves as the Chief Scientific Officer and Co-Founder of Turbine, a company focused on cancer research and treatment innovation.1
Professional Background
Dr. Veres has an extensive background in medicine and oncology:
- He obtained his Doctor of Medicine (MD) degree from Semmelweis University between 2007 and 2013.1
- He completed his Doctor of Philosophy (PhD) in Oncology and Cancer Biology from the same institution from 2013 to 2017.1
- He has held research positions at prestigious institutions, including the University of Cambridge and The Institute of Cancer Research.1
Role at Turbine
As the Chief Scientific Officer at Turbine since July 2020, Dr. Veres:
- Translates computational results from Simulated Cells into clinical interpretations.1
- Guides teams of biologists, translational scientists, and data scientists to generate novel findings for better cancer treatments.1
- Focuses on understanding scientific and medical challenges facing biopharma partners.1
Additional Experience
Dr. Veres has a diverse professional background:
- He worked as an Emergency Physician for FŐNIX-MED Zrt. from 2013 to 2016.1
- He has been a Research Fellow at Semmelweis University since November 2018.1
- He served as a Mentor and Module Leader at the Milestone Institute from 2014 to 2017.1
Achievements
Dr. Veres was recognized in the Forbes 30 Under 30 list in May 2018, highlighting his contributions to his field at a young age.1
Daniel Veres combines his medical expertise, research experience, and entrepreneurial spirit to drive innovation in cancer treatment through his work at Turbine.
Highlights
Join our wonderful new lab in Budapest, and make a difference in cancer research!
Hardest year so far for Turbine? Maybe. Most exciting year so far for Turbine? Definitely. What does it take to get through? A team led by scientific curiosity, similarly to a torch during night hiking.
This year we went even deeper to biology. We have demonstrated the in vivo effect of our simulation-first cancer target, while we have also dived into elucidating the real pharmacology of multiple late stage assets. Places, where we have never been before.
Next year we will start some super exciting partnerships, open our new lab, and hopefully deliver further proof points about how simulation-first drug discovery is providing novel insights on the road to delivering clinical benefit as the ultimate goal.
Thank you team Turbine for pushing hard but smart as always, and also big thanks to all our advisors, investors, friends who help us along the way!
See you in 2023 :)
#simulationfirst #deepbiology #drugdiscovery #team
